LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
All content for i3 Health Podcast is the property of i3 Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
Additional Insights in Dedifferentiated Liposarcoma With Richard F. Riedel, MD, and Candace L. Haddox, MD
i3 Health Podcast
37 minutes 31 seconds
3 months ago
Additional Insights in Dedifferentiated Liposarcoma With Richard F. Riedel, MD, and Candace L. Haddox, MD
As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July.
After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit.
Click the links below for the Task Force activity!
- Accredited CME/AAPA Podcast: https://i3health.com/course-information/podcast-ddlps
- Position Statement Published in Cancer Treatment Reviews: https://www.cancertreatmentreviews.com/article/S0305-7372(24)00175-0/fulltext
- Live Task Force Recording: https://youtu.be/Otr5_tiFQ68
i3 Health Podcast
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
